P. D. MITCHELL ET AL.
Copyright © 2013 SciRes. OJRD
72
and J. L. Myers, “Significance of Multiple Carcinoid Tu-
mors and Tumorlets in Surgical Lung Specimens: Analy-
sis of 28 Patients,” Chest, Vol. 131, No. 6, 2007, pp.
1635-1643. doi:10.1378/chest.06-2788
[7] R. R. Miller and N. L. Muller, “Neuroendocrine Cell
Hyperplasia and Obliterative Bronchiolitis in Patients
with Peripheral Carcinoid Tumors,” American Journal of
Surgical Pathology, Vol. 19, No. 6, 1995, pp. 653-658.
doi:10.1097/00000478-199506000-00005
[8] E. Seregni, L. Ferrari, E. Bajetta, A. Martinetti and E.
Bombardieri, “Clinical Significance of Blood Chromo-
granin a Measurement in Neuroendocrine Tumours,” An-
nals of Oncology, Vol. 12, Suppl. 2, 2001, pp. S69-S72.
doi:10.1093/annonc/12.suppl_2.S69
[9] J. S. Lee, K. K. Brown, C. Cool and D. A. Lynch, “Dif-
fuse Pulmonary Neuroendocrine Cell Hyperplasia: Ra-
diologic and Clinical Features,” Journal of Computer As-
sisted Tomography, Vol. 26, No. 2, 2002, pp. 180-184.
doi:10.1097/00004728-200203000-00003
[10] A. Gorshtein, D. Gross, D. Barak, Y. Strenov, Y. Refaeili,
I. Shimon and S. Grozinsky-Glasinshy, “Diffuse Idio-
pathic Pulmonary Neuroendocrine Cell Hyperplasia and
the Associated Lung Neuroendocrine Tumours: Clinical
Experience with a Rare Entity,” Cancer, Vol. 118, No. 3,
2012, pp. 612-619. doi:10.1002/cncr.26200
[11] S. Dacic, “Pulmonary Preneoplasia,” Archives of Pathol-
. Jaroszewski, R. Helmers and T. Colby
ams, A. R. Dodson and C. S. Fos-
.2011.03992.x
ogy & Laboratory Medicine, Vol. 132, No. 7, 2008, pp.
1073-1078.
[12] A. Nasser, D,
“Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hy-
perplasia: A Systematic Overview,” American Journal of
Respiratory and Critical Care Medicine, Vol. 184, No.
18-16, 2011, pp. 8-16.
[13] J. R. Gosney, I. J. Willi
ter, “Morphology and Antigen Expression Profile of Pul-
monary Neuroendocrine Cells in Reactive Proliferations
and Diffuse Idiopathic Pulmonary Neuroendocrine Cell
Hyperplasia (DIPNECH),” Histopathology, Vol. 59, No.
4, 2011, pp. 751-762.
doi:10.1111/j.1365-2559
M. E. Sunday[14] S. Degan, G. Y. Lopez, K. Kevill and,
“Gastrin-Releasing Peptide, Immune Responses, and
Lung Disease,” Annals of the New York Academy of Sci-
ences, Vol. 1144, 2008, pp. 136-147.
doi:10.1196/annals.1418.022
[15] EGFR, “Expression in Pulmonary Neuroendocrine Cell
Hyperplasia,” Pathologe, Vol. 27, No. 2, 2006, pp. 147-
151. doi:10.1007/s00292-006-0819-0
[16] A. Warth, E. Herpel, A. Schmähl, K. Storz and P. A.
Schnabel, “Diffuse Idiopathic Pulmonary Neuroendocrine
Cell Hyperplasia (DIPNECH) in Association with an
Adenocarcinoma: A Case Report,” Journal of Medical
Case Reports, Vol. 2, 2008, p. 21.
doi:10.1186/1752-1947-2-21
[17] L. Salz, “Octreotide as an Antineoplastic Agent in the
Treatment of Functional and Nonfunctional Neuroendo-
crine Tumors,” Cancer, Vol. 72, No. 1, 1993, pp. 244-248.
doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR
2820720143>3.0.CO;2-Q
[18] J. Chan and M. Kulke, “Progress in the Treat ment of Neu-
8-0
roendocrine Tumors,” Current Oncology Reports, Vol. 11,
No. 3, 2009, pp. 193-199.
doi:10.1007/s11912-009-002
. Miller, M. I. Schwarz [19] M. B. Fessler, C. D. Cool, Y. E
and K. K. Brown, “Idiopathic diffuse Hyperplasia of Pul-
monary Neuroendocrine Cells in a Patient with Acro-
megaly,” Respirology, Vol. 9, No. 2, 2004, pp. 274-277.
doi:10.1111/j.1440-1843.2004.00571.x
[20] M. S. Sanaee, P. M. O’Byrne and P. Nair, “Diffuse Idio-
pathic Pulmonary Neuroendocrine Hyperplasia, Chronic
Eosinophilic Pneumonia, and Asthma,” European Respi-
ratory Journal, Vol. 34, No. 6, 2009, pp. 1489-1492.
doi:10.1183/09031936.00109409
[21] E. N. Coletta, L. R. Voss, M. S. Lima, J. S. Arakaki, J.
. Bo-
Camara, C. D’Andretta Neto and C. A. Pereira, “Diffuse
Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Accompanied by Airflow Obstruction,” Jornal Brasileiro
de Pneumologia, Vol. 35, No. 5, 2009, pp. 489-494.
[22] S. M. Aguayo, Y. E. Miller, J. A. Waldron Jr., R. M
gin, M. E. Sunday, G. W. Staton Jr, W. R. Beam and T. E.
King Jr., “Brief Report: Idiopathic Diffuse Hyperplasia of
Pulmonary Neuroendocrine Cells and Airways Disease,”
New England Journal of Medicine, Vol. 327, 1992, pp.
1285-1288. doi:10.1056/NEJM199210293271806
[23] L. Saltz, “Octreotide as an antineoplastic Agent in the
Treatment of Functional and Non-Functional Neuroendo-
crine Tumours,” Cancer, Vol. 72, No. 1, 1993, p p. 244-248.
doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR
2820720143>3.0.CO;2-Q
[24] J. Chan and M. Kulke, “Progress in the Treatment of
Neuroendocrine Tumors,” Current Oncology Reports, Vol.
11, No. 3, 2009, pp. 193-199.
doi:10.1007/s11912-009-0028-0